Key result
Dual antiplatelet loading in HBR ACS patients is linked to ~71% higher in-hospital mortality and bleeding.
Why the study?
Guidelines support dual antiplatelet therapy loading doses for ACS, but limited data exist for patients with high bleeding risk undergoing PCI.
Does a loading dose of dual antiplatelet therapy improve in-hospital mortality or bleeding in patients with acute coronary syndrome and high bleeding risk undergoing PCI?
Observational (n=21,654)
Yes
Does a loading dose of dual antiplatelet therapy improve in-hospital mortality or bleeding in patients with acute coronary syndrome and high bleeding risk undergoing PCI?
In ACS patients with high bleeding risk undergoing PCI, administering a loading dose of dual antiplatelet therapy is associated with increased in-hospital mortality and bleeding.
Answers are grounded in this paper and cite their sources.
Loading doses were associated with higher mortality and bleeding; leaves open whether RCTs would alter this in high-bleeding-risk ACS.
Objective Loading dose of dual antiplatelet therapy (LD) is supported by the guidelines for patients with acute coronary syndrome (ACS). However, limited data is provided in the series of high bleeding risk (HBR) patients with ACS and percutaneous coronary intervention (PCI). Methods Using data from the Improving Care for Cardiovascular Disease in China—Acute Coronary Syndrome registry, conducted between 2014 and 2019, we stratified all ACS patients with HBR and PCI according to LD used within 24 h of first medical contact or not. Inverse probability of treatment weighting (IPTW) and Cox proportional hazards model with hospital as random effect were used to analyze differences in in-hospital clinical outcomes: the primary efficacy endpoint was mortality, and the primary safety endpoint was bleeding. Results Of 21,654 evaluable patients 14,322 (66.2%) were treated with LD, and were on average older, less likely to have comorbidities and higher hemoglobin, more often treated GPI and anticoagulant during hospitalization than those without LD. After IPTW adjustment for baseline differences, LD was associated with significantly increased risk of in-hospital mortality [1.89 vs. 1.02%; hazard ratio (HR): 1.71 (95% confidence interval 1.12, 2.42); p < 0.001] and in-hospital bleeding [3.89 vs. 3.3%; HR: 1.25 (1.03, 1.53); p = 0.03]. Conclusions In ACS patients with HBR, LD was associated with an increased risk of in-hospital mortality and bleeding complications after PCI. Dedicated randomized trials with contemporary ACS management are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2022) conducted an observational in Acute Coronary Syndrome with High Bleeding Risk (n=21,654). Dual loading antiplatelet therapy (aspirin and P2Y12 inhibitor) vs. No dual loading dose was evaluated on In-hospital mortality (HR 1.71, 95% CI 1.12-2.42, p=<0.001). Dual loading antiplatelet therapy in acute coronary syndrome patients with high bleeding risk increased in-hospital mortality and bleeding compared to no loading dose.
Synapse has enriched 10 related papers. Consider them for comparative context: